Ardent Health Partners Inc. (ARDT)
NYSE NYSE Primary 
Ardent Health, Inc. (ARDT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ardent Health, Inc. (ARDT) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ardent Health, Inc. (ARDT) Q1 2026 Earnings Call Transcript
Ardent Health, Inc. (ARDT) Q1 2026 Earnings Call Transcript
Ardent Health, Inc. (ARDT) Q4 2025 Earnings Call Transcript
Ardent Health, Inc. (ARDT) Q4 2025 Earnings Call Transcript
Ardent Health, Inc. (ARDT) Lags Q4 Earnings and Revenue Estimates
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.32 per share, missing the Zacks Consensus Estimate of $0.35 per share. This compares to earnings of $0.81 per share a year ago.
This Stock Is Pumping Huge Cash For Its Price
We believe Ardent Health (ARDT) stock is worth considering: It is growing, generating cash, and is priced at a notable valuation discount. Companies of this caliber can utilize cash to drive further revenue growth, or simply reward their shareholders through dividends or buybacks.
Could Ardent Health Be A Value Buy Right Now?
We believe Ardent Health (ARDT) stock deserves attention: It is growing, generating cash, and is priced significantly below its valuation. Companies like this can utilize cash to drive further revenue growth or distribute it to their shareholders via dividends or buybacks.
New Strong Sell Stocks for Nov. 18th
DIOD, ARDT and FFIV have been added to the Zacks Rank #5 (Strong Sell) List on November 18, 2025.
Ardent Health, Inc. (ARDT) Q3 2025 Earnings Call Transcript
Ardent Health, Inc. ( ARDT ) Q3 2025 Earnings Call November 13, 2025 9:00 AM EST Company Participants David Styblo - Senior Vice President of Investor Relations Martin Bonick - President, CEO & Director Alfred Lumsdaine - Chief Financial Officer Conference Call Participants Jason Cassorla - Guggenheim Securities, LLC, Research Division Benjamin Mayo - Leerink Partners LLC, Research Division Scott Fidel - Goldman Sachs Group, Inc., Research Division Kevin Fischbeck - BofA Securities, Research Division Zach Haggerty Raj Kumar - Stephens Inc., Research Division Craig Hettenbach - Morgan Stanley, Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Desiree, and I will be your conference operator today.
Ardent Health, Inc. (ARDT) Surpasses Q3 Earnings and Revenue Estimates
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.19 per share a year ago.
Ardent Health, Inc. (ARDT) Q2 Earnings and Revenues Surpass Estimates
Ardent Health, Inc. (ARDT) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.35 per share a year ago.
Analysts Estimate Ardent Health, Inc. (ARDT) to Report a Decline in Earnings: What to Look Out for
Ardent Health, Inc. (ARDT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ardent Health: The Best Prospect In An Industry That's Facing Challenges
Ardent Health faces significant legislative risks, due to Medicaid and Medicare cuts, causing uncertainty and a recent downgrade, but much of this is priced in. Despite headwinds, Ardent Health demonstrates strong revenue and profitability growth, low leverage, and trades at compellingly cheap valuations, versus peers. Management projects continued growth for 2025, with revenue and EBITDA expected to rise, supported by higher-margin service expansions and acquisitions.
